venbeta6890
mAbexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 11, 2025 (NCT06896136)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Heat-stable enterotoxin receptorINHIBITOR
GUCY2C inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06896136 | Phase 1 | Feb 11, 2025 | Bill and Melinda Gates Foundation, Pharmaron, University of Maryland, University of Massachusetts |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Pharmaron | For profit | 1 | 0 | 1 | 2025 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Massachusetts | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1